Another Analysis of Trastuzumab for Only 9 Weeks: Not an Option Another Analysis of Trastuzumab for Only 9 Weeks: Not an Option
A 9-week course of trastuzumab for low- and intermediate-risk early breast cancer looks possible but is not recommended as a standard of care according to experts.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news